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Diagnostic methods for mastitis in cows




Healthcare workers are now being targeted for marketing of diagnostic tools for mastitis that were developed
for the dairy industry and which aim to provide information regarding choice of antibiotic treatment. Meanwhile,
scientists are striving to understand how the human microbiome affects health and wellbeing and the importance of
maintenance of bacterial balance in the human body. Breast milk supplies a multitude of bacteria to populate
the baby’s intestinal tract and kick-start the immune system. Researchers propose a paradigm shift in the understanding
of bacterial content in breast milk and an alternative paradigm for the understanding of lactational mastitis: there is the
beginning of evidence that many cases of lactational mastitis will resolve spontaneously. An international group
of researchers is attempting to answer how dietary habits, birth mode, genetics and environmental factors may
impact the bacterial content of breast milk. Until we have more comprehensive knowledge about the human milk
microbiome, diagnostic aids for identification of women in need of antibiotic therapy for mastitis remain unreliable.
Diagnostic aids could lead to the injudicious use of antibiotic therapy, which in turn may rob the infant of bacteria
valuable for development of its immune system. The marketing of diagnostic aids for use in human medicine, that
were originally developed for use in cows, is neither evidence-based nor good ethical practice.
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Background
A lactation problem common to both animals and
humans is mastitis. The development of new knowledge
can be enhanced if we open our minds to the fact that
there must be many similarities between the mammals of
our planet. We must, however, also remember that there
are very many “specifics” that govern how we view disease
in domestic animals and in humans. The dairy industry is
a multi-billion dollar industry in many high-income coun-
tries whereas the production of human milk is not usually
seen as a revenue-generating occupation (even though in
recent years breast milk has been marketed on the World
Wide Web). The content of cows’ milk is very carefully
monitored and an outbreak of bovine mastitis in a dairy
farm can be a very costly problem when the milk cannot
be sold due to either bacterial or antibiotic contamination.
In both the European Union and the US, antimicrobial
residue in milk renders it unfit for sale [1, 2]. This would
seem to be a counter-incentive to the injudicious use of
antibiotics. However, the US Department of Agriculture
stated in 2008 that almost all dairy cows receive prophy-
lactic intra-mammary infusions of antibiotics after each
lactation to prevent and control future mastitis [3]. A large
number of internationally recognized experts in infection
control convened in 2011 and reported that in order to
contain the increasing threat to human health posed by
resistant bacteria there is an urgent need for regulation on
a global level of antibiotic use in food animals [4].
Main text
After an extended weekend break in July 2015, I returned
to my desk and opened my mail box–the usual onslaught
of messages waited. I’ve learnt by now how to scan the title
of mails and to quickly gauge the caliber and interest of the
messages. It’s particularly easy to dismiss marketing mails;
students and research take precedence over commerce.
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This day, however, I pause a moment before discarding an
obvious marketing mail because the word “mastitis” jumps
out at me. I’ve been researching mastitis in breastfeeding
women for a decade and a half. That, of course, is
the reason why I was targeted for the marketing mail.
So what was the sales pitch? The market development
manager wondered if I would be interested in qPCR
(quantative polymerase chain reaction) analysis of milk
from women with mastitis needing antibiotic treatment,
which would give an answer within 3–4 h. The test was
originally developed for use in the dairy industry but the
firm is now looking to make inroads into the area of
human mastitis using the latest DNA diagnostic tests.
New techniques for identification of bacterial DNA
have sparked intense interest in that which is now
termed the human microbiome. The systematic study of
the human microbiome is a relatively new area of scien-
tific research but one that is being given considerable
attention in the media. An important reason for this
attention is the belief that the human microbiome has
profound effects on human health. Of the hundreds of
thousands of different kinds of microbes on earth, about
1000 have been shown to be associated with humans [5].
Hundreds of thousands of years of evolution have fine-
tuned the production of the best nutrition available for
human babies but it is now being demonstrated that
breast milk also supplies a multitude of bacteria to
populate the baby’s intestinal tract and kick-start the
immune system. Scientists are now asking themselves
which microbes are the important ones for human
health and in what quantities they need to be present in
order to avoid a “dysbiosis”, which can be defined as a
disruption in the balance of microbial colonization in
human biological systems.
An international group of researchers is currently
gathering material from four continents in order to at-
tempt to answer questions related to the composition of
breast milk, including the microbiome, in a study which
has been funded by the National Science Foundation in
the US under the working name “INSPIRE: What is
normal milk?”
Although the true incidence of mastitis in lactating
women is unknown [6], it is estimated that approxi-
mately 10 % of breastfeeding women experience one or
more episodes of mastitis [7]. Mastitis is most com-
monly diagnosed by the observation of signs and symp-
toms, both localized to the breast and also systemic
symptoms which may make women feel extremely ill.
Women may have a mixture of the following: tense
breasts not relieved by breastfeeding and/or lumps in
the breast tissue, breast redness, pyrexia and pain. Breast
pain alone is not indicative of lactational mastitis. Scien-
tists have shown a surprisingly diverse collection of bac-
teria in breast milk from healthy women [8–11] of
which several are considered to be potential pathogens.
Although Staphylococcus aureus has often been cited as
the most common causative organism for mastitis, as
many as 31 % of healthy breastfeeding women harbour
Staphylococcus aureus in their breast milk and 10 %
harbour GBS (Group B streptococci). What is more,
these bacteria were found in the same concentrations as
in women with mastitis [9]. Researchers from Australia
have recently pointed out that the role of potentially
pathogenic bacteria in the aetiology of lactational mas-
titis in humans is not known [12]. It is apparent then,
that identification of bacteria in breast milk, whether by
culture-dependent or culture-independent methods, is
not yet a reliable means to decide on treatment with
antibiotic therapy. This may seem a shocking statement
to make, since it has earlier been reported that in
Australia between 77 and 89 % of women with mastitis
symptoms are prescribed antibiotics [13–15] on the
basis of breast milk culture and reports from the USA
show that between 86 and 97 % of women with symptoms
were given oral antibiotics [16, 17]. Fear of litigation is
certainly one reason for this apparent overuse but
also the “quick fix” ethos of our times is surely at work
here. Scandinavians have tended to a more restrictive use
of antibiotics, 38 % in a study from Finland [18] and 15 %
in a Swedish trial [19]. More recently, researchers from
both the US and Australia have proposed a paradigm shift
in the understanding of bacterial content in breast milk
[12, 20]. Ingman et al. [12] also suggest an alternative
paradigm for the understanding of the disease process in
lactational mastitis and conclude that specific inflamma-
tory signalling pathways activated in the individual woman
may determine her susceptibility to mastitis and that not
only potentially pathogenic bacteria but also commensal
microbiota contribute to this signalling.
Until recently, the preferred methods of identifying
bacterial agents involved in the formation of human
mastitis have been culture-based, meaning that bacteria
from milk were cultured on specific growth media. The
bacterial colonies were subsequently identified to species
and numbers of colony forming units (cfu). New tech-
niques, such as species-specific qPCR, which was the
kind of analysis offered to me, aim at quantifying the
amounts of DNA for predefined bacterial groups present
in a sample. The important word here is “predefined”.
The qPCR analyses offered to me in the marketing mail
pre-supposes that certain types and amounts of bacteria
found to be present in a milk sample indicate a case of
mastitis, in need of antibiotic treatment. The success of
the proposed analyses in identifying the true agents of
mastitis therefore pre-supposes the precision and
breadth of prior results, as well as the accuracy of the
hypothesis that bacteria found in the breast milk of
women with symptoms of mastitis are not present in
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milk from healthy breasts; a presupposition that is not
founded in the scientific literature. The overarching
assumption of companies that claim to enable quick and
accurate human mastitis diagnoses presumes that we
know the full spectrum of the breast milk microbiome
and of bacterial agents involved in mastitis. This is
belied both by current research findings [8, 9, 12] and
the significance that the INSPIRE project has been
funded by an important national body.
Two researchers very well versed in the area of anti-
biotic resistance remind us that modern medicine has
saved numerous lives through treatment of severe infec-
tions with antibiotics and through medical and surgical
procedures carried out under the protection of antibiotics
[21]. They tell us also that the golden era of antibiotic
discovery is over. We are all steadily coming to accept the
threat to world health that antibiotic resistant bacterial
strains can lead to and we have a responsibility to our-
selves, our children and our children’s children to do what
is in our power to halt the growing threat. Within health-
care services this entails not only strict adherence to
hygiene regulations but also paying attention to research
that might give clues to areas where antibiotics might be
used injudiciously. One well known example of research
that has changed the use of antibiotic therapy is acute
otitis media in children. There is now a comprehensive
bank of evidence suggesting that most cases of otitis
media in children will resolve spontaneously [22]. There is
the beginning of evidence that this may also be the case
with lactational mastitis in humans [9, 12, 20] but we will
not know for sure until results of the INSPIRE project are
available and until well-designed randomized controlled
trials of antibiotics for the treatment of human lactational
mastitis are carried out [23]. Until then, the bacterial
agents and disease pathways involved in human mastitis
cannot be claimed to be diagnosable.
Conclusion
A research question that has recently arisen is how the
human milk microbiome might vary depending on dietary
habits, delivery mode, genetics and environmental factors.
Until we have more knowledge about the human milk
microbiome, diagnostic aids for identification of women
in need of antibiotic therapy for mastitis remain unreli-
able. Using them may entail a risk of injudicious use of
antibiotic therapy, thereby robbing the infant of bacteria
valuable for its immune response and adding to problems
associated with antibiotic resistance. I suggest that the
marketing of these products for use in human medicine is
neither evidence based nor good ethical practice.
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